Trial Profile
A Randomized, Double-blind, Placebo-controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 2 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents (CAIN457F2302) and a Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Rheumatoid Arthritis (CAIN457F2302E1)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary) ; Secukinumab (Primary)
- Indications Rheumatoid arthritis
- Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms REASSURE
- Sponsors Novartis
- 08 Mar 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 18 Feb 2015 Planned End Date changed from 1 Mar 2017 to 1 Oct 2016 as reported by ClinicalTrials.gov
- 18 Feb 2015 Planned primary completion date changed from 1 Mar 2017 to 1 Oct 2016 as reported by ClinicalTrials.gov